What Is The Current and Historic Market Size Analysis Of The Buccal Drug Delivery System Market?
The buccal drug delivery system market has seen considerable growth due to a variety of factors.
• In recent times, the market size for the buccal drug delivery system has seen significant expansion. The market is projected to rise from a worth of $3.55 billion in 2024 to $3.91 billion in 2025, maintaining a compound annual growth rate (CAGR) of 10.3%. Factors fostering the growth during the historic period include advancements in early drug delivery, adoption by the pharmaceutical industry, the effectiveness established through clinical studies, strategies for market penetration, and specific applications for different diseases.
What Are The Predictions for The Buccal Drug Delivery System Market Size In The Coming Years?
The Buccal Drug Delivery System market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of the buccal drug delivery system is projected to experience swift expansion in the upcoming years, reaching a value of $5.97 billion by 2029 with a compound annual growth rate (CAGR) of 11.1%.
This surge during the forecast period is attributed to factors such as the prioritization of patient-oriented drug delivery, an increasing elderly population, the need for specialized therapies, as well as biologics and peptide delivery, regulatory assistance and approvals, and investments in research and development. Key tendencies forecasted for the period encompass patient comfort and adherence to treatment, advancements in drug formulation, an increase in chronic illnesses, and more focus on pediatric and geriatric care, all contributing to enhanced bioavailability.
Which Drivers Are Accelerating Growth In The Buccal Drug Delivery System Market?
The escalating prevalence of chronic illnesses is predicted to drive the expansion of the buccal drug delivery systems market in the future. Chronic diseases are defined as conditions that last for a year or more, including diseases like cancer, heart disease, stroke, diabetes, and arthritis. These are the most common long-term conditions that can be controlled but not completely cured, necessitating ongoing medical care and nutritional support. Buccal drug delivery systems offer suitable and efficient medication administration for mucosal and transmucosal drugs required by numerous patients with chronic diseases like diabetes and cancer. For example, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that there were 41 million deaths, accounting for 74% of all deaths caused by non-communicable diseases (NCDs) or chronic diseases globally each year. The deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the increasing prevalence of chronic diseases is fuelling the growth of the buccal drug delivery systems market.
What Are The Core Segments Of The Global Buccal Drug Delivery System Market?
The buccal drug delivery system market covered in this report is segmented –
1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users
Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels
Pre-Book The Buccal Drug Delivery System Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Buccal Drug Delivery System Market Size?
Leading organizations in the buccal drug delivery systems market are channeling their efforts into the creation of groundbreaking solutions like oral treatments for plaque psoriasis, with the aim to elevate patient results and boost the effectiveness of drug delivery. The term oral treatment for plaque psoriasis involves the ingestion of medications to control and soothe the indicators of plaque psoriasis, an enduring autoimmune disorder characterized by an accelerated rate of skin cell growth that results in thick, red and flaky skin patches. For example, Bristol Myers Squibb, an American pharmaceutical firm, was granted FDA approval for Sotyktu (deucravacitinib), an oral therapy for adults affected by moderate to severe plaque psoriasis, in September 2022. This authorization signifies the first fresh oral treatment for this particular condition in approximately ten years, presenting a unique method of effects as a selective inhibitor of tyrosine kinase 2 (TYK2).
Who Are the Key Players In The Buccal Drug Delivery System Market?
Major companies operating in the buccal drug delivery system market include:
• Teva Pharmaceuticals Industries Ltd.
• Pfizer Incorporated
• GlaxoSmithKline Public Limited Company
• Indivior PLC
• Generex Biotechnology Corporation
• Catalent Inc.
• Arx Limited Liability Company
• BioDelivery Science International Incorporated
• Cynapsus Therapeutics Incorporated
• Endo Pharmaceuticals Public Limited Company
• Medlab Clinical Ltd.
• AstraZeneca PLC
• F Hoffmann-La Roche Limited
• Dr. Reddy’s Laboratories Ltd.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Novo Nordisk A/S
• Ethypharm SAS
• Applied Pharma Research SA
• Sunovion Pharmaceuticals Inc.
• Sanofi SA
• Bayer AG
• Adare Pharmaceuticals Inc.
• NAPP Pharmaceutical Ltd.
• Perrigo Company PLC
• Reckitt Benckiser Group PLC
• Teligent Pharma Inc.
• Par Pharmaceutical Companies Inc.
• Acorda Therapeutics Inc.
• Opiant Pharmaceuticals Inc.
What Are The Regional Insights Into The Buccal Drug Delivery System Market?
North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
